261 related articles for article (PubMed ID: 32356926)
1. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.
Rothlin RP; Vetulli HM; Duarte M; Pelorosso FG
Drug Dev Res; 2020 Nov; 81(7):768-770. PubMed ID: 32356926
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
3. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
5. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
7. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
[TBL] [Abstract][Full Text] [Related]
8. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis.
Panigrahi S; Goswami T; Ferrari B; Antonelli CJ; Bazdar DA; Gilmore H; Freeman ML; Lederman MM; Sieg SF
Microbiol Spectr; 2021 Dec; 9(3):e0073521. PubMed ID: 34935423
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2, ACE2 expression, and systemic organ invasion.
Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG
Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540
[TBL] [Abstract][Full Text] [Related]
11. Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19.
Batchu SN; Kaur H; Yerra VG; Advani SL; Kabir MG; Liu Y; Klein T; Advani A
Diabetes; 2021 Mar; 70(3):759-771. PubMed ID: 33310740
[TBL] [Abstract][Full Text] [Related]
12. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19.
Pedrosa MA; Valenzuela R; Garrido-Gil P; Labandeira CM; Navarro G; Franco R; Labandeira-Garcia JL; Rodriguez-Perez AI
Clin Sci (Lond); 2021 Feb; 135(3):465-481. PubMed ID: 33479758
[TBL] [Abstract][Full Text] [Related]
13. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury.
Yamaguchi T; Hoshizaki M; Minato T; Nirasawa S; Asaka MN; Niiyama M; Imai M; Uda A; Chan JF; Takahashi S; An J; Saku A; Nukiwa R; Utsumi D; Kiso M; Yasuhara A; Poon VK; Chan CC; Fujino Y; Motoyama S; Nagata S; Penninger JM; Kamada H; Yuen KY; Kamitani W; Maeda K; Kawaoka Y; Yasutomi Y; Imai Y; Kuba K
Nat Commun; 2021 Nov; 12(1):6791. PubMed ID: 34815389
[TBL] [Abstract][Full Text] [Related]
14. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.
Parit R; Jayavel S
Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.
Gurwitz D
Drug Dev Res; 2020 Aug; 81(5):537-540. PubMed ID: 32129518
[TBL] [Abstract][Full Text] [Related]
16. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
Wang Y; Takeshita H; Yamamoto K; Huang Y; Wang C; Nakajima T; Nozato Y; Fujimoto T; Yokoyama S; Hongyo K; Nakagami F; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Rakugi H
FASEB J; 2021 Mar; 35(3):e21419. PubMed ID: 33566370
[TBL] [Abstract][Full Text] [Related]
17. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
18. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
19. Elovanoids downregulate SARS-CoV-2 cell-entry, canonical mediators and enhance protective signaling in human alveolar cells.
Calandria JM; Bhattacharjee S; Maness NJ; Kautzmann MI; Asatryan A; Gordon WC; Do KV; Jun B; Mukherjee PK; Petasis NA; Bazan NG
Sci Rep; 2021 Jun; 11(1):12324. PubMed ID: 34112906
[TBL] [Abstract][Full Text] [Related]
20. Soluble ACE2 as a potential therapy for COVID-19.
Krishnamurthy S; Lockey RF; Kolliputi N
Am J Physiol Cell Physiol; 2021 Mar; 320(3):C279-C281. PubMed ID: 33502950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
